Remdesivir linked with COVID-19 clinical improvement and safetyRemdesivir treatment of hospitalized patients with noncritical COVID-19 is associated with better clinical improvement, shorter recovery and hospital stays, and safety, according to a meta-analysis of five randomized clinical trials published today in the Journal of Antimicrobial Chemotherapy.
No significant association was found in regards to mortality.The studies covered 13,544 adult patients from at least 30 countries, of which 391 received a 5-day regimen and 3,839 received a 10-day regimen.
Of the studies, which were published from Jan 1 to Nov 18, 2020, three were open-label, and two were double-blind.Patients who received a 5-day regimen had greater clinical improvement